|
1
|
Quattrin T, Mastrandrea LD and Walker LSK:
Type 1 diabetes. Lancet. 401:2149–2162. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Subramanian S, Khan F and Hirsch IB: New
advances in type 1 diabetes. BMJ. 384:e0756812024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang W, Ling Q, Wang B, Wang K, Pang J,
Lu J, Bi Y and Zhu D: Comparison of therapeutic effects of
mesenchymal stem cells from umbilical cord and bone marrow in the
treatment of type 1 diabetes. Stem Cell Res Ther. 13:4062022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Primavera R, Regmi S, Yarani R, Levitte S,
Wang J, Ganguly A, Chetty S, Guindani M, Ricordi C, Meyer E and
Thakor AS: Precision delivery of human bone marrow-derived
mesenchymal stem cells into the pancreas via intra-arterial
injection prevents the onset of diabetes. Stem Cells Transl Med.
13:559–571. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Madani S, Amanzadi M, Aghayan HR, Setudeh
A, Rezaei N, Rouhifard M and Larijani B: Investigating the safety
and efficacy of hematopoietic and mesenchymal stem cell
transplantation for treatment of T1DM: A systematic review and
meta-analysis. Syst Rev. 11:822022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Lima KA, de Oliveira GL, Yaochite JN,
Pinheiro DG, de Azevedo JT, Silva WA Jr, Covas DT, Couri CE, Simões
BP, Voltarelli JC, et al: Transcriptional profiling reveals
intrinsic mRNA alterations in multipotent mesenchymal stromal cells
isolated from bone marrow of newly-diagnosed type 1 diabetes
patients. Stem Cell Res Ther. 7:922016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carlsson PO, Schwarcz E, Korsgren O and Le
Blanc K: Preserved β-cell function in type 1 diabetes by
mesenchymal stromal cells. Diabetes. 64:587–592. 2015. View Article : Google Scholar
|
|
8
|
Dharmadhikari G, Stolz K, Hauke M, Morgan
NG, Varki A, de Koning E, Kelm S and Maedler K: Siglec-7 restores
β-cell function and survival and reduces inflammation in pancreatic
islets from patients with diabetes. Sci Rep. 7:453192017.
View Article : Google Scholar
|
|
9
|
Bandala-Sanchez E, Zhang Y, Reinwald S,
Dromey JA, Lee BH, Qian J, Böhmer RM and Harrison LC: T cell
regulation mediated by interaction of soluble CD52 with the
inhibitory receptor Siglec-10. Nat Immunol. 14:741–748. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo M, Guo H, Zhu J, Wang F, Chen J, Wan
C, Deng Y, Wang F, Xu L, Chen Y, et al: A novel subpopulation of
monocytes with a strong interferon signature indicated by SIGLEC-1
is present in patients with in recent-onset type 1 diabetes.
Diabetologia. 67:623–640. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He F, Wang N, Li J, He L, Yang Z, Lu J,
Xiong G, Yu C and Wang S: High affinity monoclonal antibody
targeting Siglec-15 for cancer immunotherapy. J Clin Transl Res.
7:739–749. 2021.
|
|
12
|
Wang J, Sun J, Liu LN, Flies DB, Nie X,
Toki M, Zhang J, Song C, Zarr M, Zhou X, et al: Siglec-15 as an
immune suppressor and potential target for normalization cancer
immunotherapy. Nat Med. 25:656–666. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu J, Yu A, Othmane B, Qiu D, Li H, Li C,
Liu P, Ren W, Chen M, Gong G, et al: Siglec15 shapes a non-inflamed
tumor microenvironment and predicts the molecular subtype in
bladder cancer. Theranostics. 11:3089–3108. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo H, Shen Y, Kong YH, Li S, Jiang R, Liu
C, Fang C and Hu J: The expression of Tim-1 and Tim-4 molecules in
regulatory T cells in type 1 diabetes. Endocrine. 68:64–70. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Angata T and Varki A: Discovery,
classification, evolution and diversity of siglecs. Mol Aspects
Med. 90:1011172023. View Article : Google Scholar
|
|
16
|
American Diabetes Association: 2.
Classification and diagnosis of diabetes: Standards of medical care
in diabetes-2021. Diabetes Care. 44:S15–S33. 2021. View Article : Google Scholar
|
|
17
|
Ansari MJ, Salama AD, Chitnis T, Smith RN,
Yagita H, Akiba H, Yamazaki T, Azuma M, Iwai H, Khoury SJ, et al:
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes
in nonobese diabetic (NOD) mice. J Exp Med. 198:63–69. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Hiruma Y, Hirai T and Tsuda E: Siglec-15,
a member of the sialic acid-binding lectin, is a novel regulator
for osteoclast differentiation. Biochem Biophys Res Commun.
409:424–429. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Du H, Tang J, Li X, Wang X, Wu L, Zhang R,
Hu P and Yang Y: Siglec-15 is an immune suppressor and potential
target for immunotherapy in the pre-metastatic lymph node of
colorectal cancer. Front Cell Dev Biol. 9:6919372021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kucia M, Reca R, Jala VR, Dawn B,
Ratajczak J and Ratajczak MZ: Bone marrow as a home of heterogenous
populations of nonhematopoietic stem cells. Leukemia. 19:1118–1127.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ji JF, He BP, Dheen ST and Tay SS:
Interactions of chemokines and chemokine receptors mediate the
migration of mesenchymal stem cells to the impaired site in the
brain after hypoglossal nerve injury. Stem Cells. 22:415–427. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ratajczak J, Wysoczynski M, Zuba-Surma E,
Wan W, Kucia M, Yoder MC and Ratajczak MZ: Adult murine bone
marrow-derived very small embryonic-like stem cells differentiate
into the hematopoietic lineage after coculture over OP9 stromal
cells. Exp Hematol. 39:225–237. 2011. View Article : Google Scholar
|
|
24
|
Izadi M, Sadr Hashemi Nejad A, Moazenchi
M, Masoumi S, Rabbani A, Kompani F, Hedayati Asl AA, Abbasi
Kakroodi F, Jaroughi N, Mohseni Meybodi MA, et al: Mesenchymal stem
cell transplantation in newly diagnosed type-1 diabetes patients: A
phase I/II randomized placebo-controlled clinical trial. Stem Cell
Res Ther. 13:2642022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu H and Mahato RI: Mesenchymal stem
cell-based therapy for type 1 diabetes. Discov Med. 17:139–143.
2014.PubMed/NCBI
|
|
26
|
Zhou T, Yuan Z, Weng J, Pei D, Du X, He C
and Lai P: Challenges and advances in clinical applications of
mesenchymal stromal cells. J Hematol Oncol. 14:242021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gou W, Hua W, Swaby L, Cui W, Green E,
Morgan KA, Strange C and Wang H: Stem cell therapy improves human
islet graft survival in mice via regulation of macrophages.
Diabetes. 71:2642–2655. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Özçelik H, Yazır Y, Duruksu G, Kılıç KC
and Öztürk A: Membrane-engineered Wharton's Jelly derived
mesenchymal stem cells with anti-CD2 antibody coating modulate
activated CD3+ T-cell responses. Tissue Cell. 99:1032742026.
View Article : Google Scholar
|
|
29
|
Khazaei M, Khazaei F, Niromand E and
Ghanbari E: Tissue engineering approaches and generation of
insulin-producing cells to treat type 1 diabetes. J Drug Target.
31:14–31. 2023. View Article : Google Scholar
|
|
30
|
Luque-Campos N, Contreras-López RA, Jose
Paredes-Martínez M, Torres MJ, Bahraoui S, Wei M, Espinoza F,
Djouad F, Elizondo-Vega RJ and Luz-Crawford P: Mesenchymal stem
cells improve rheumatoid arthritis progression by controlling
memory T cell response. Front Immunol. 10:7982019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Higdon LE, Cooney LA, Serti E, Suwannasaen
D, Muir VS, Wiedeman AE, Harris KM, Pardo J, Anderson MS, Speake C,
et al: Early expansion of TIGIT+PD1+ effector memory CD4 T cells
via agonistic effect of alefacept in new-onset type 1 diabetes. J
Immunol. 214:12–22. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao Y, Knight CM, Jiang Z, Delgado E, Van
Hoven AM, Ghanny S, Zhou Z, Zhou H, Yu H, Hu W, et al: Stem cell
educator therapy in type 1 diabetes: From the bench to clinical
trials. Autoimmun Rev. 21:1030582022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Passeri L, Andolfi G, Bassi V, Russo F,
Giacomini G, Laudisa C, Marrocco I, Cesana L, Di Stefano M, Fanti
L, et al: Tolerogenic IL-10-engineered dendritic cell-based therapy
to restore antigen-specific tolerance in T cell mediated diseases.
J Autoimmun. 138:1030512023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Luo X, Pothoven KL, McCarthy D, DeGutes M,
Martin A, Getts DR, Xia G, He J, Zhang X, Kaufman DB and Miller SD:
ECDI-fixed allogeneic splenocytes induce donor-specific tolerance
for long-term survival of islet transplants via two distinct
mechanisms. Proc Natl Acad Sci USA. 105:14527–14532. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Golden GJ, Wu VH, Hamilton JT, Amses KR,
Shapiro MR, Sada Japp A, Liu C, Pampena MB, Kuri-Cervantes L, Knox
JJ, et al: Immune perturbations in human pancreas lymphatic tissues
prior to and after type 1 diabetes onset. Nat Commun. 16:46212025.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang Y, Xu Z, Wu KL, Yu L, Wang C, Ding H,
Gao Y, Sun H, Wu YH, Xia M, et al: Siglec-15/sialic acid axis as a
central glyco-immune checkpoint in breast cancer bone metastasis.
Proc Natl Acad Sci USA. 121:e23129291212024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lenza MP, Egia-Mendikute L,
Antoñana-Vildosola A, Soares CO, Coelho H, Corzana F, Bosch A,
Manisha P, Quintana JI, Oyenarte I, et al: Structural insights into
Siglec-15 reveal glycosylation dependency for its interaction with
T cells through integrin CD11b. Nat Commun. 14:34962023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang XY, Shi JB, Jin SF, Wang RJ, Li MY,
Zhang ZY, Yang X and Ma HL: Metabolic landscape of head and neck
squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis
in immune escape. Cancer Commun (Lond). 44:670–694. 2024.
View Article : Google Scholar : PubMed/NCBI
|
